After the first discovery of epidermal growth factor receptor (EGFR) oncogenic mutations in non-small cell lung cancer (NSCLC), EGFR-tyrosine kinase inhibitors (TKIs) became the standard treatment [1]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.